Chlorambucil <i>versus</i> observation after anti‐<i>Helicobacter</i> therapy in gastric MALT lymphomas: results of the international randomised LY03 trial
Barry W. Hancock(Weston Park Cancer Centre), Emanuele Zucca(Università della Svizzera italiana), Ira Jakupovic(Cancer Research UK), Franco Cavalli(Institute of Social and Preventive Medicine), Sergio Cortelazzo(Azienda Ospedaliero-Universitaria delle Marche), Cathy Burton(Cancer Research UK), Giovanni Martinelli(University of Bologna), Catherine Traullé(Université de Lyon), Christiane Copie‐Bergman, Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Christian Gisselbrecht(Institut Universitaire de France), Michaël Lévy(Assistance Publique – Hôpitaux de Paris), Wendi Qian(MRC Clinical Trials Unit at UCL), Carlo Capella(University of Insubria), Achille Ambrosetti(International Extranodal Lymphoma Study Group), Paul Smith(Cancer Research UK), Jean‐Charles Delchier(Assistance Publique – Hôpitaux de Paris), Andrew Wotherspoon(Université Libre de Bruxelles), Graziella Pinotti(Medica (Italy)), Umberto Vitolo(Candiolo Cancer Institute), Robert L. Souhami(Cancer Research UK), David C. Linch(University of Oxford)
Cited by 60
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751